Lindsay Rosenwald
Chief Executive Officer chez FORTRESS BIOTECH, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Lindsay Allan Rosenwald was the founder of TG Therapeutics, Inc. (founded in 2012), Paramount BioCapital Asset Management, Inc. (founded in 1991), Keryx Biopharmaceuticals, Inc. (founded in 1994), Cougar Biotechnology, Inc. (founded in 2003), Paramount BioSciences LLC (founded in 1991), Opus Point Partners Management LLC (founded in 2009), Helocyte, Inc. (founded in 2015), and Cyprium Therapeutics, Inc. (founded in 2017).
Dr. Rosenwald's current job(s) include Executive Chairman, President & CEO at Fortress Biotech, Inc. (since 2009), Executive Chairman at Cellvation, Inc., Executive Chairman at Journey Medical Corp., Non-Executive Director at Checkpoint Therapeutics, Inc. (since 2014), Director at Avenue Therapeutics, Inc. (since 2015), Non-Executive Director at Mustang Bio, Inc. (since 2015), Director at Caelum Biosciences, Inc., and Director at Baergic Bio, Inc.Dr. Rosenwald's former job(s) include Chairman & Chief Executive Officer at Paramount BioCapital, Inc. (from 1991 to 2008), Co-Chairman & Chief Executive Officer at Origo Acquisition Corp.
(from 2014 to 2016), Chairman at Paramount Acquisition Corp., Managing Director at D.H.
Blair & Co., Inc. (from 1987 to 1992), and Securities Analyst at Ladenburg Thalmann & Co., Inc.Dr. Rosenwald's education history includes an undergraduate degree from The Pennsylvania State University and a doctorate degree from Temple University School of Medicine (conferred in 1983).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FORTRESS BIOTECH, INC.
15,58% | 27/03/2024 | 2 863 905 ( 15,58% ) | 6 M $ | 31/03/2024 |
JOURNEY MEDICAL CORP.
2,56% | 25/03/2024 | 320 715 ( 2,56% ) | 1 M $ | 31/03/2024 |
| 19/03/2024 | 50 123 ( 0,22% ) | 102 752 $ | 31/03/2024 | |
| 09/01/2024 | 361 429 ( 0,82% ) | 53 130 $ | 31/03/2024 | |
MUSTANG BIO, INC.
0,28% | 08/03/2024 | 27 191 ( 0,28% ) | 28 279 $ | 31/03/2024 |
Postes actifs de Lindsay Rosenwald
| Sociétés | Poste | Début |
|---|---|---|
| FORTRESS BIOTECH, INC. | Chief Executive Officer | 20/12/2013 |
| CHECKPOINT THERAPEUTICS, INC. | Director/Board Member | 10/11/2014 |
| AVENUE THERAPEUTICS, INC. | Director/Board Member | 07/03/2023 |
| MUSTANG BIO, INC. | Director/Board Member | 13/03/2015 |
| JOURNEY MEDICAL CORPORATION | Chairman | - |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The private company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Founder | 01/01/2017 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | - |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Founder | 01/01/2015 |
| Cellvation, Inc. | Chairman | - |
| ░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Lindsay Rosenwald
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Lindsay Rosenwald
| The Pennsylvania State University | Undergraduate Degree |
| Temple University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| CHECKPOINT THERAPEUTICS, INC. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| JOURNEY MEDICAL CORPORATION | Health Technology |
| Entreprise privées | 16 |
|---|---|
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Founded in 1991 by Dr. Lindsay Rosenwald, Paramount BioCapital Asset Management, Inc. is a hedge fund manager located in New York City. The firm is a subsidiary of Paramount BioCapital, Inc. | Finance |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Paramount BioCapital, Inc.
 Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | Finance |
Paramount Acquisition Corp.
 Paramount Acquisition Corp. Financial ConglomeratesFinance Paramount Acquisition Corp. was incorporated in Delaware on June 1, 2005 as a blank check company with a objective to acquire an operating business. It is a newly organized Specified Purpose Acquisition Company. The purpose of its incorporation is effecting a merger, capital stock exchange, asset acquisition or other similar business combination with an operating business in the healthcare industry. | Finance |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Health Technology |
Ladenburg Thalmann & Co., Inc.
 Ladenburg Thalmann & Co., Inc. Investment Banks/BrokersFinance Ladenburg Thalmann & Co., Inc. provides investment baking and brokerage services. The firm also provides asset and wealth management, underwriting, alternative investments and advisory services. It serves emerging growth companies and high net worth individuals. The company was founded in 1876 and is headquartered in New York, NY. | Finance |
Paramount BioSciences LLC
 Paramount BioSciences LLC Investment ManagersFinance Paramount BioSciences LLC (Paramount) is a venture capital firm founded in 1991. The firm is headquartered in New york. | Finance |
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Finance |
| D.H. Blair & Co., Inc. | |
Origo Acquisition Corp.
 Origo Acquisition Corp. Financial ConglomeratesFinance Origo Acquisition Corp. is a blank check company. It seeks to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company was founded on August 26, 2014 and is headquartered in New York, NY. | Finance |
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Commercial Services |
| Mustang Bio, Inc. | |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The private company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Commercial Services |
| Cellvation, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Health Technology |
